Eterna Integrative Team
Candida albicans already lives in most human guts. It isn’t an invader picked up somewhere; it’s a normal resident, present in an estimated 50 to 60 percent of healthy adults without causing a single symptom. That fact reframes the usual question. It’s rarely about whether candida is present. It’s about whether something has let it grow past its normal boundaries, and whether the candida overgrowth symptoms someone is dealing with, the fatigue, bloating, or brain fog, actually trace back to yeast at all.
When Candida Is Actually the Problem
Real overgrowth has a mechanism behind it. Broad-spectrum antibiotics wipe out the bacteria that normally compete with candida for space and nutrients, and gut studies show this directly increases candida’s foothold in the intestine. Immune suppression, uncontrolled blood sugar, and a damaged gut lining do something similar: they remove the checks that usually keep this fungus in its lane. In someone recovering from a course of antibiotics, managing poorly controlled diabetes, or on immunosuppressive medication, an overgrowth is a real, measurable shift, and it tends to respond to treatment aimed directly at it.
That’s a narrower group of people than the internet’s version of “candida overgrowth” suggests. A lot of what gets that label today is a vague cluster of fatigue, brain fog, joint aches, and mood changes, treated as though yeast must be the common thread. The clearest data point against that assumption is older but still holds up: in a randomized, placebo-controlled trial, women diagnosed with so-called candidiasis hypersensitivity syndrome were given either oral nystatin or a placebo, and the two groups improved similarly. Killing the yeast didn’t move the symptoms, which means the yeast likely wasn’t driving them.
This is the actual judgment call in candida functional medicine: telling apart overgrowth with a clear cause and a measurable response to antifungal treatment from a symptom picture where candida is a bystander to something else entirely, whether that’s an inflamed gut lining, bacterial dysbiosis, poor sleep, or chronic stress. Good practice starts by ruling out the second category before treating the first.
Testing Approaches, and What the Evidence Actually Supports
Three tests get used, and they measure three different things. Stool testing, whether culture-based or DNA-based, can identify candida directly, but a positive result doesn’t reliably separate normal colonization from true overgrowth, since yeast isn’t distributed evenly through a stool sample. Antibody testing (IgG, IgA) mostly tells you that exposure happened at some point; it can’t say whether that was last month or several years ago. Urine organic acids testing, which measures compounds like arabinose and arabinitol, gets marketed as a window into gut yeast, but the research backing it comes almost entirely from invasive, bloodstream infections in immunocompromised patients, not everyday gut overgrowth in otherwise healthy people. Arabinose specifically has other dietary and microbial sources, which opens the door to false positives.
None of these tests, alone, delivers a clean yes or no. A more honest approach uses two or three of them together, read against the person’s actual history: recent antibiotic use, blood sugar control, immune status, and symptom timeline. A single elevated marker on a urine panel isn’t a diagnosis by itself.
Yeast Overgrowth Treatment: Diet and Medication That Hold Up
The reasoning behind a low-sugar, low-refined-carbohydrate diet is straightforward: candida ferments sugar for fuel, and glucose supports both its growth and its ability to form protective biofilms. There’s real clinical evidence behind this, not just theory. A pilot study following 120 patients with confirmed intestinal candida overgrowth found that at the three-month mark, 85 percent had improved on the recommended diet, compared with 42.5 percent in the group given antifungal medication alone. Diet outperformed the drug over time, which is a useful corrective for anyone assuming a prescription alone will solve this.
A similar pattern shows up in an unrelated group. Fibromyalgia patients placed on a carbohydrate-restricted diet saw measurable drops in fungal abundance in the gut, alongside an increase in the kind of bacteria that produce beneficial short-chain fatty acids. Cutting the fuel supply changes the gut environment in a fairly consistent way across different patient groups.
For medication, the two mainstays work differently. Nystatin stays in the gut, isn’t absorbed into the bloodstream, and targets yeast in the colon without disturbing beneficial bacteria as much as a systemic drug would. Fluconazole is absorbed and circulates throughout the body, which makes it useful when overgrowth has moved beyond the gut but also means it interacts with more of the body’s normal microbial balance. Which one makes sense, if either does, depends on how confirmed and how extensive the overgrowth actually is.
Probiotics play a supporting role rather than a starring one. Saccharomyces boulardii, a yeast-based probiotic, competes with candida for the same real estate and nutrients. In a placebo-controlled trial in people living with HIV, twelve weeks of S. boulardii reduced bacterial translocation markers and systemic inflammation tied to gut barrier health. That’s a different kind of benefit than direct antifungal killing. It points to probiotics shoring up the gut environment that normally keeps candida in check, which matters most as a long-term maintenance strategy rather than an acute fix.
Putting It Together
A workable protocol layers three things: cutting the sugar that feeds overgrowth, matching antifungal treatment to what testing and history actually show, and supporting the bacterial environment that keeps candida in its normal, harmless role. None of this works well as a guess, and given how often the “candida overgrowth” label gets stretched to cover symptoms that have nothing to do with yeast, the first real question is whether there’s overgrowth to treat at all. That’s easier to sort out with a clinician who can weigh test results against the whole picture, rather than reacting to one urine marker in isolation.